MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program

Rhea-AI Summary

Mangoceuticals (NASDAQ: MGRX) reported early traction for a newly launched all-inclusive injectable Testosterone Replacement Therapy (TRT) program priced at $99/month. MangoRx cites 336% month-over-month sales growth since mid-December and a 54% reduction in customer acquisition cost.

The offer includes doctor visits, labs, and prescribed medication. Management expects TRT to be the primary near-term growth driver while expanding telehealth men’s health services and maintaining regulatory compliance.

Positive

• Sales +336% MoM since mid-December
• CAC -54% for the injectable TRT program
• $99/month all-inclusive pricing covering visits, labs, and medication
• Company positions TRT as primary growth driver going forward

Negative

• Initial results reflect a short post-launch window since mid-December
• Market CAGR ~3.9% implies modest long-term market expansion

News Market Reaction – MGRX

+2.22% 210.7x vol

35 alerts

+2.22% News Effect

+60.5% Peak in 17 hr 24 min

+$236K Valuation Impact

$11M Market Cap

210.7x Rel. Volume

On the day this news was published, MGRX gained 2.22%, reflecting a moderate positive market reaction. Argus tracked a peak move of +60.5% during that session. Our momentum scanner triggered 35 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $236K to the company's valuation, bringing the market cap to $11M at that time. Trading volume was exceptionally heavy at 210.7x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

TRT program price: $99 per month MoM TRT sales growth: 336% CAC reduction: 54% +2 more

5 metrics

TRT program price $99 per month All-inclusive injectable TRT treatment program

MoM TRT sales growth 336% Month-over-month sales increase since mid-December launch

CAC reduction 54% Reduction in customer acquisition cost for injectable TRT program

Global TRT market size $2.11–$2.2 billion Estimated 2025 global testosterone replacement therapy market

TRT market CAGR 3.9% Projected compound annual growth rate for global TRT market

Market Reality Check

Price: $0.5253 Vol: Volume 80,041 is about 0....

low vol

$0.5253 Last Close

Volume Volume 80,041 is about 0.24x the 20-day average of 337,160, indicating muted trading interest into this news. low

Technical Shares at $0.36 are trading below the 200-day MA of $1.57 and remain far under the 52-week high of $6.15.

Peers on Argus

MGRX is up 2.22% while peers show mixed, mostly negative moves (e.g., STRM, DRIO...

MGRX is up 2.22% while peers show mixed, mostly negative moves (e.g., STRM, DRIO, ZCMD down; HCTI and VSEE up), and no peers appeared in the momentum scanner. This points to a stock-specific reaction tied to the TRT update rather than a sector-wide move.

Historical Context

5 past events · Latest: Dec 19 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 19	Financing closed	Negative	-45.6%	Closing of $2.5M registered direct and private placements under existing shelf.
Dec 19	Crypto DAT strategy	Neutral	-45.6%	Launch of up to $100M Solana-focused digital asset treasury strategy with partner.
Dec 18	Financing announced	Neutral	+7.4%	Announcement of $2.5M registered direct and private placements priced at market.
Nov 13	GLP-1 clarification	Neutral	-32.4%	Clarification on GLP‑1 weight‑management programs and lack of big-pharma contracts.
Nov 13	GLP-1 access launch	Neutral	-32.4%	Launch of GLP‑1 telehealth access programs with fixed cash-pay pricing and memberships.

Pattern Detected

Recent history shows large negative reactions (down 32–46%) around financings and controversial partnership/clarification releases, suggesting the stock has been highly sensitive to capital-raising and strategic announcements.

Recent Company History

Over the last six months, Mangoceuticals has focused on capital markets activity and telehealth product expansion. In Nov 2025, it launched MangoRx Direct and PeachesRx Direct GLP‑1 programs with memberships at $99/month, followed by a clarification release the same day; shares fell over 32%. In Dec 2025, the company announced and then closed $2.5M in registered direct and private placements, alongside a Solana‑focused DAT partnership, with about 45% one‑day downside. Today’s TRT growth update fits the ongoing telehealth men’s health strategy but follows a period of heavy dilution and volatility.

Market Pulse Summary

This announcement highlights rapid traction in MangoRx’s injectable TRT program, with 336% month‑ove...

Analysis

This announcement highlights rapid traction in MangoRx’s injectable TRT program, with 336% month‑over‑month sales growth and a 54% reduction in customer acquisition costs at a $99/month price point. It reinforces the company’s telehealth-focused men’s health strategy alongside prior GLP‑1 offerings. Investors may watch whether this translates into higher reported revenue, reduced losses noted in recent SEC filings, and progress on maintaining Nasdaq listing compliance while the TRT market, estimated at $2.11–$2.2B, grows at 3.9% CAGR.

Key Terms

testosterone replacement therapy, customer acquisition cost, cac, compound annual growth rate, +3 more

7 terms

testosterone replacement therapy medical

"all-inclusive injectable Testosterone Replacement Therapy (TRT) treatment program priced at $99"

Testosterone replacement therapy is a medical treatment that restores low levels of the hormone testosterone using products such as injections, gels, patches or implants, similar to refilling a fuel tank when a car is running low. It matters to investors because demand, product approvals, safety concerns, and insurance coverage directly affect the revenues and risks for drugmakers, device makers and clinics involved in producing and delivering these treatments.

customer acquisition cost financial

"Month over month growth of 336% and 54% Reduction in Customer Acquisition Cost (CAC)"

The amount of money a company spends, on average, to win a single new customer, including marketing, sales and any onboarding costs. Investors care because it shows how efficiently a business grows: if the cost to acquire customers is lower than the revenue those customers bring over time, the company can scale profitably—think of it as the price paid to plant one seed and whether that seed yields a healthy tree.

cac financial

"increased 336% since launching in mid-December while at the same time reducing customer acquisition costs by 54%"

Customer acquisition cost (CAC) is the average amount a company spends to win one paying customer, including marketing, sales and onboarding expenses. Investors watch CAC because it shows how efficiently a business grows: like measuring the fuel needed to add one mile to a car’s odometer, a low CAC relative to the revenue a customer generates suggests the company can scale profitably, while a high CAC may signal costly growth or thin margins.

compound annual growth rate financial

"projected to grow at a compound annual growth rate (CAGR) of around 3.9%"

The compound annual growth rate (CAGR) shows how much an investment or value has grown, on average, each year over a specific period. It considers the effect of growth that compounds or builds upon itself, similar to how interest accumulates in a savings account. Investors use CAGR to compare different investments’ long-term performance and to understand how steady or consistent their growth has been over time.

cagr financial

"projected to grow at a compound annual growth rate (CAGR) of around 3.9%"

Compound Annual Growth Rate (CAGR) measures the average yearly growth of an investment, revenue, or other metric over a multi-year period as if it had grown at a steady rate each year. Think of it like the constant speed that would take you from the starting value to the ending value over the same time—useful because it smooths out ups and downs and lets investors compare different assets or performance periods on an even footing.

telehealth technical

"optimize marketing efficiency and patient access through its proprietary telehealth platform"

Telehealth is the delivery of healthcare services and consultations remotely using video calls, phone, text messaging, or connected devices to monitor and transmit medical information. It matters to investors because it can reshape how patients access care, lower costs, and create new revenue streams or risks for healthcare providers, insurers and technology companies—similar to how online banking changed financial services—while also exposing businesses to reimbursement and regulatory shifts.

hypogonadism medical

"greater awareness of hypogonadism symptoms, and advancements in various formulations"

Hypogonadism is a medical condition in which the body produces abnormally low levels of sex hormones because the glands that make them are underactive or not working properly. For investors, it matters because diagnosis and long-term treatment can drive demand for drugs, devices and tests, affect clinical trial activity and influence regulatory and reimbursement decisions—similar to how a faulty thermostat can create ongoing repair and replacement markets.

AI-generated analysis. Not financial advice.

Month over Month Growth of 336% and 54% Reduction in Customer Acquisition Cost (CAC)

DALLAS, TX, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (the “Company” or “MangoRx”), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that MangoRx has experienced initial success for its newly launched all-inclusive injectable Testosterone Replacement Therapy (TRT) treatment program priced at $99 per month. The new TRT offer includes all doctor visits and medical consultations, lab work and analysis, and the medication to the extent prescribed. More information about MangoRx’s $99 per month offer can be found here at https://trt.mangorx.com/products/trt.

Month over month sales of MangoRx’s injectable TRT treatment program have increased 336% since launching in mid-December while at the same time reducing customer acquisition costs by 54%.

We believe that this strong momentum reflects growing demand for convenient, effective TRT options and MangoRx’s focused efforts to optimize marketing efficiency and patient access through its proprietary telehealth platform. We expect TRT to be the primary growth driver for the Company going forward, as MangoRx continues to prioritize and invest in advancing its TRT offerings, including both injectable and oral formulations such as PRIME by MangoRx, powered by Kyzatrex®, to attempt to capture greater market share in this high-demand segment.

“We are encouraged by this initial customer demand and sales acceleration in our injectable TRT product, which we believe demonstrates the value of our innovative approach to men’s hormone health and underscores TRT as our key strategic focus,” commented Jacob Cohen, Founder and CEO of Mangoceuticals Inc. “By combining effective TRT solutions with streamlined telehealth delivery and targeted cost efficiencies, we are seeking to become better positioned to support more men seeking reliable, discreet care. At the same time, we are committed to building a more comprehensive platform that delivers a wider range of wellness solutions, which we expect to strengthen our operational and financial foundation and position us for sustained growth.”

According to The Business Research Company’s Testosterone Replacement Therapy Global Market Report (2026 edition), the global testosterone replacement therapy market is valued at approximately $2.11 billion to $2.2 billion in 2025 and is projected to grow at a compound annual growth rate (CAGR) of around 3.9% in the coming years, fueled by an aging population, greater awareness of hypogonadism symptoms, and advancements in various formulations that offer improved convenience.

Looking ahead, MangoRx is working to evolve its telehealth platform to become a more well-rounded provider of men’s health and wellness solutions. By expanding beyond specialization in single treatments, the Company plans to offer an increasingly diverse array of pharmaceutical-based products, addressing a broader range of men’s health needs while maintaining its core strength in hormone optimization and TRT.

The Company remains committed to patient safety and regulatory compliance. All MangoRx and TRT related products are prescribed exclusively through licensed healthcare providers following thorough medical evaluations and including appropriate lab testing where and when necessary.

About Mangoceuticals, Inc.

MangoRx is focused on developing a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the Company currently offers pharmaceutical-based products specifically related to the treatments of erectile dysfunction, hair growth, hormone replacement therapies, and weight management. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a licensed medical provider and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com.

Cautionary Note Regarding Forward-Looking Statements

Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). These forward-looking statements represent the Company’s current expectations or beliefs concerning future events and can generally be identified using statements that include words such as “estimate,” “expects,” “project,” “believe,” “anticipate,” “intend,” “plan,” “foresee,” “forecast,” “likely,” “will,” “target” “up to” or similar words or phrases. These forward-looking statements include, but are not limited to, the review and evaluation of strategic transactions and their impact on shareholder value; the process by which the Company engages in evaluation of strategic transactions; the outcome of potential future strategic transactions and the terms thereof; macroeconomic, industry and market conditions, including inflation, interest rate volatility, recessionary trends, financial market disruptions, changes in regulatory or political environments, and other factors beyond the Company’s control that could adversely affect its business, financial condition and results of operations; our ability to meet the continued listing requirements of Nasdaq and maintain the listing of our common stock on Nasdaq, including as a result of our current non-compliance with certain listing standards relating to our stock price; our ability to successfully undertake a crypto treasury strategy in the future; risks related to the significant number of shares in the public float, our share volume, the effect of sales of a significant number of shares in the marketplace; dilution caused by offerings; conversion of outstanding shares of preferred stock and the rights and preferences thereof, the fact that we have a significant number of outstanding warrants to purchase shares of common stock and other convertible securities, the resale of which underlying shares have been registered under the Securities Act of 1933, as amended, dilution caused by exercises/conversions thereof, overhang related thereto, and decreases in the trading price of our common stock caused by sales thereof; our ability to build and maintain our brands; cybersecurity, information systems, fraud and website risks; compliance with applicable laws and regulations affecting our operations, products, marketing, manufacturing, labeling and distribution; shipping, production and supply chain delays; reliance on third parties for prescribing, compounding and other key services; product safety risks; macroeconomic and geopolitical conditions, including inflation, interest rates, recessions, pandemics, acts of war, tariffs and trade disruptions; protection of intellectual property; our ability to attract and retain key personnel; potential stock overhang and volatility in the trading price of our common stock; and consumer sentiment and discretionary spending trends. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements we make in this release are reasonable, we provide no assurance that these plans, intentions or expectations will be achieved. Consequently, you should not consider any such list to be a complete set of all potential risks and uncertainties.

More information on potential factors that could affect the Company’s financial results is included from time to time in the “Cautionary Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, and subsequent reports. These filings are available at www.sec.gov and at our website at https://www.mangoceuticals.com/sec-filings. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

FOR INVESTOR RELATIONS
Mangoceuticals Investor Relations
Email: investors@mangorx.com

FAQ

What growth did MangoRx (MGRX) report for its $99 injectable TRT program on Feb 19, 2026?

MangoRx reported 336% month-over-month sales growth since mid-December. According to MangoRx, this reflects initial post-launch momentum and targeted marketing efficiencies driving early adoption.

How much did MangoRx (MGRX) reduce customer acquisition cost for the injectable TRT offering?

MangoRx reported a 54% reduction in customer acquisition cost for the injectable TRT program. According to MangoRx, improved marketing efficiency and telehealth access helped lower acquisition expenses.

What does MangoRx’s $99/month TRT program include for patients (MGRX)?

The $99/month plan includes doctor visits, medical consultations, lab work, and prescribed medication. According to MangoRx, all products are prescribed through licensed healthcare providers after medical evaluation.

Will MangoRx (MGRX) rely on TRT as a growth driver after Feb 19, 2026?

MangoRx expects TRT to be its primary growth driver going forward. According to MangoRx, the company will prioritize and invest in both injectable and oral TRT offerings to capture market share.

How large is the global TRT market cited by MangoRx in the Feb 19, 2026 announcement?

MangoRx cited a global TRT market valued at approximately $2.11–$2.2 billion in 2025 with a projected CAGR of about 3.9%. According to MangoRx, this estimate is from an industry market report.

Are MangoRx’s TRT products prescribed and compliant with regulations (MGRX)?

Yes. MangoRx states all TRT products are prescribed exclusively through licensed healthcare providers with appropriate lab testing. According to MangoRx, the company remains committed to patient safety and regulatory compliance.